TY - JOUR
TI - Use of statins and risk of haematological malignancies: A meta-analysis of six randomized clinical trials and eight observational studies
AU - Bonovas, S.
AU - Filioussi, K.
AU - Tsantes, A.
AU - Sitaras, N.M.
JO - British Journal of Clinical Pharmacology
PY - 2007
VL - 64
TODO - 3
SP - 255-262
PB - 
SN - 0306-5251, 1365-2125
TODO - 10.1111/j.1365-2125.2007.02959.x
TODO - fluindostatin;  hydroxymethylglutaryl coenzyme A reductase inhibitor;  mevinolin;  placebo;  pravastatin;  simvastatin, article;  case control study;  clinical trial;  cohort analysis;  confidence interval;  data analysis;  disease association;  drug safety;  hematologic malignancy;  human;  meta analysis;  methodology;  observational study;  outcome assessment;  priority journal;  publishing;  randomization;  risk factor;  systematic review, Epidemiologic Studies;  Female;  Hematologic Neoplasms;  Humans;  Hydroxymethylglutaryl-CoA Reductase Inhibitors;  Male;  Middle Aged;  Randomized Controlled Trials as Topic;  Risk Factors;  Treatment Outcome
TODO - Aims: Statins have been suggested to prevent haematological malignancies. Several epidemiological studies have evaluated this association, while randomized controlled trials (RCTs) on cardiovascular outcomes have provided relevant data as secondary end-points. Our aim was to examine the strength of this association through a detailed meta-analysis of the studies published in peer-reviewed literature. Methods: A comprehensive search for articles published up to December 2006 was performed, reviews of each study were conducted and data abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using the random effects model. Results: Fourteen studies (six RCTs, seven case-control and one cohort study) contributed to the analysis. Studies were grouped on the basis of study design, and two separate meta-analyses were conducted. There was no evidence of an association between statin use and haematological malignancies among either RCTs (RR = 0.92, 95% CI 0.72, 1.16) or the observational studies (RR = 0.83, 95% CI 0.53, 1.29). Similarly, we found no evidence of publication bias. However, high heterogeneity was detected among the observational studies. Conclusion: Our meta-analysis findings do not support a potential role of statins in the prevention of haematological malignancies. © 2007 The Authors.
ER -